Browse NPHS2

Summary
SymbolNPHS2
Namenephrosis 2, idiopathic, steroid-resistant (podocin)
Aliases SRN1; PDCN; Podocin
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cell membrane Peripheral membrane protein ; SUBCELLULAR LOCATION: Isoform 2: Endoplasmic reticulum
Domain PF01145 SPFH domain / Band 7 family
Function

Plays a role in the regulation of glomerular permeability, acting probably as a linker between the plasma membrane and the cytoskeleton.

> Gene Ontology
 
Biological Process GO:0001655 urogenital system development
GO:0001656 metanephros development
GO:0001822 kidney development
GO:0002064 epithelial cell development
GO:0007588 excretion
GO:0031532 actin cytoskeleton reorganization
GO:0032835 glomerulus development
GO:0035850 epithelial cell differentiation involved in kidney development
GO:0061005 cell differentiation involved in kidney development
GO:0061318 renal filtration cell differentiation
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072009 nephron epithelium development
GO:0072010 glomerular epithelium development
GO:0072015 glomerular visceral epithelial cell development
GO:0072073 kidney epithelium development
GO:0072112 glomerular visceral epithelial cell differentiation
GO:0072202 cell differentiation involved in metanephros development
GO:0072207 metanephric epithelium development
GO:0072210 metanephric nephron development
GO:0072224 metanephric glomerulus development
GO:0072243 metanephric nephron epithelium development
GO:0072244 metanephric glomerular epithelium development
GO:0072248 metanephric glomerular visceral epithelial cell differentiation
GO:0072249 metanephric glomerular visceral epithelial cell development
GO:0072310 glomerular epithelial cell development
GO:0072311 glomerular epithelial cell differentiation
GO:0072312 metanephric glomerular epithelial cell differentiation
GO:0072313 metanephric glomerular epithelial cell development
Molecular Function -
Cellular Component GO:0009898 cytoplasmic side of plasma membrane
GO:0031235 intrinsic component of the cytoplasmic side of the plasma membrane
GO:0036056 filtration diaphragm
GO:0036057 slit diaphragm
GO:0045121 membrane raft
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolNPHS2
Namenephrosis 2, idiopathic, steroid-resistant (podocin)
Aliases SRN1; PDCN; Podocin
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NPHS2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolNPHS2
Namenephrosis 2, idiopathic, steroid-resistant (podocin)
Aliases SRN1; PDCN; Podocin
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NPHS2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNPHS2
Namenephrosis 2, idiopathic, steroid-resistant (podocin)
Aliases SRN1; PDCN; Podocin
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NPHS2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9162.0870.0318
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.3040.355
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 473.0910.0489
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6210.175
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NPHS2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNPHS2
Namenephrosis 2, idiopathic, steroid-resistant (podocin)
Aliases SRN1; PDCN; Podocin
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NPHS2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNPHS2
Namenephrosis 2, idiopathic, steroid-resistant (podocin)
Aliases SRN1; PDCN; Podocin
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NPHS2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NPHS2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNPHS2
Namenephrosis 2, idiopathic, steroid-resistant (podocin)
Aliases SRN1; PDCN; Podocin
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NPHS2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNPHS2
Namenephrosis 2, idiopathic, steroid-resistant (podocin)
Aliases SRN1; PDCN; Podocin
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NPHS2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNPHS2
Namenephrosis 2, idiopathic, steroid-resistant (podocin)
Aliases SRN1; PDCN; Podocin
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NPHS2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNPHS2
Namenephrosis 2, idiopathic, steroid-resistant (podocin)
Aliases SRN1; PDCN; Podocin
Chromosomal Location1q25.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NPHS2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.